All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Mutation testing in AML:
What you need to know
with Charles Craddock, Ralph Hills, and Gail Roboz
Wednesday, April 23, 2025
17:30-18:30 BST
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through a grant from Bristol Myers Squibb and Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Visual abstract | Phase III trial of Iomab-B versus conventional conditioning pre-HSCT in patients with R/R AML (SIERRA)
By Ella Dixon
Bookmark this article
The AML Hub is pleased to present a visual abstract summarizing key results from the randomized phase III SIERRA trial comparing Iomab-B prior to hematopoietic stem cell transplant (HSCT) with conventional care in patients with relapsed or refractory acute myeloid leukemia.1
These data were presented by Giralt1 at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, where Giralt highlighted the key safety and efficacy findings from this pivotal trial of Iomab-B, a first-in-class anti-CD45-conjugated radiotherapy. Older patients with relapsed/refractory acute myeloid leukemia have a poor prognosis, with high rates of failure often preventing access to HSCT. Improving conditioning regimens may therefore result in better HSCT outcomes for these patients.1
- Giralt S. Efficacy and safety results of the Sierra trial: A multicenter, pivotal phase III study of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in older patients with active, relapsed or refractory acute myeloid leukemia (R/R AML). Oral abstract #LBA3. 2023 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR; Feb 18, 2023; Orlando, US.
Your opinion matters
2 votes - 23 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox